ArticleIJTLD open2025
A longitudinal analysis of the economic cost of all phases of TB care in a low incidence setting.
Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur objective was to estimate the attributable health care costs associated with TB in Ontario, Canada.
methodsWe conducted an incidence-based matched cohort study among individuals diagnosed with TB between April 1, 2002 to December 31, 2016. We matched exposed individuals 1:2 to unexposed individuals using hard and propensity score matching. Using phase-of-care costing, we calculated the mean attributable costs of TB, standardized to 10-day cost, for seven phases of illness: pre-diagnosis, initial treatment, continuation phase, remainder year 1, year 2, post-TB, and prior-to-death. We estimated survival-adjusted attributable mean 1-, 2-, and 5-year costs.
resultsWe matched 6,456 individuals with TB to 12,443 individuals without TB. Mean (95% CI) attributable 10-day costs was highest in the pre-death phase at $2,656 ($2,207, $3,104), followed by the initial treatment phase at $1,693 ($1,608, $1,778). Hospitalization costs were the largest cost component in each phase. The mean attributable 1-, 2-, and 5-year survival-adjusted costs were $25,586, $30,178, and $33,370, respectively.
conclusionIndividuals with TB have higher health care costs over their lifetime (from pre-diagnosis until death) than individuals without TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.